Cystic fibrosis is a life-limiting recessive genetic disorder caused by pathogenic variants in the CFTR gene, resulting in increased viscosity and difficult mucus clearance.

**AIM AND OBJECTIVES**

Introduction of elexacaftor (ELX) / tezacaftor (TEZ) / ivacaftor (IVA) to clinical practice has brought a change in the clinical approach, since they modulate CFTR. Our aim is to assess effectiveness and security of ELX/TEZ/IVA in our patients.

Data were collected from electronic medical records and pharmacy dispensing programs.

**MATERIAL AND METHODS**

Observational, retrospective study carried out between March-2020 and September-2022, including all adult patients treated with ELX/TEZ/IVA+IVA in our hospital.

**VARIABLES**

- Sex, age, age of diagnosis, %pFEV1, pulmonary exacerbations, treatment adjustment, adverse events and treatment suspension

**RESULTS**

31 patients (45% male), median age of 31 years (17-45), median age at diagnosis of 4 months (0-38) and median length of ELX/TEZ/IVA + IVA treatment at the moment of the analysis was 9.43 months (4.5-31.4)

<table>
<thead>
<tr>
<th>%pFEV1 during treatment augmented in 83% patients, slightly decreased in 13% and did not vary in 3,25 patients.</th>
<th>Pulmonary Exacerbations</th>
<th>Treatment Adjustment</th>
<th>Adverse Events</th>
<th>Treatment Suspension</th>
</tr>
</thead>
<tbody>
<tr>
<td>6,5% patients. Required antibiotic treatment but no hospital admission</td>
<td>3,25% patients due to interactions with potent CYP3A4 inhibitors. 3,25% patients due to hepatic insufficiency (Child-Pugh B)</td>
<td>29% patients. Increase of transaminase and/or bilirubin</td>
<td>3,25% patients temporarily discontinued treatment and 3,2% suspended treatment definitely</td>
<td></td>
</tr>
</tbody>
</table>

Before taking ELE/TEZ/IVA+IVA, 45% patients received TEZ/IVA+IVA as CFTR modulator; 55% did not receive any CFTR modulator.

**CONCLUSION AND RELEVANCE**

The introduction of ELEX/TEZ/IVA to CF treatment has been a hopeful advance that has shown in our population to have a good safety profile -which can be managed with regular check-ups- and with a good efficacy profile, achieving an increase of %pFVE1 in a short time.